YU
RNAC icon

Yale University’s Cartesian Therapeutics RNAC Stock Holding History

Yale University’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100,000
Closed -$1.61M – 4
2024
Q3 		$1.61M Hold
100,000
– – 66.3% 1
2024
Q2 		$2.7M Buy
+100,000
New +$2.39M 77.59% 1

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Yale University's RNAC Position: Q4 2024 in Review

Yale University sold out of Cartesian Therapeutics (RNAC) in Q4 2024, closing a stake of 100,000 shares — an estimated $1.61M sold.

Yale University first reported a position in RNAC in Q2 2024 and held it in 2 quarters. The position peaked at $2.7M in Q2 2024. 68 funds tracked by Wall St. Rank hold RNAC as of Q4 2024.

  • Yale University reported no remaining Cartesian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Yale University sold 100,000 Cartesian Therapeutics shares in Q4 2024, an estimated $1.61M.
  • Yale University first reported a position in Cartesian Therapeutics in Q2 2024 and held it in 2 quarters.
  • Yale University's Cartesian Therapeutics position peaked at $2.7M in Q2 2024.
  • 68 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2024.

Based on Yale University's 13F filing for Q4 2024, filed 14 Feb 2025.